Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Immediately connect with the needs of industry with your master’s degree. The new course Practical Aspects of Quality Management in Pharma and Biotech provides just that. The LACDR and LUMC set up the course together with the Biotech Training Facility, located at the Leiden Bio Science Park. The first…

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.

Sometimes an idea seems so logical and elegant at first glance, that you later wonder why no one thought of it before. Two researchers from LACDR have teamed up to develop a completely synthetic alternative to antibodies—one that mimics their size, shape and function, but which is cheaper, more stable,…

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

Leiden researcher Anne-Grete Märtson brought together a large number of studies to better understand antibiotic dosing in patients with obesity. The publication in a renowned medical journal has already garnered much positive reactions, Märtson says. ‘It’s high time researchers started sharing more…

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.

The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What’s more, the bacterium is far less likely to return, a major issue with existing antibiotics. The research was published in Nature Communications.

Read here about the various agreements in place at Leiden University for student and study associations and other student organisations.

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’

A new class of polymers has been used in patients for the first time. The compound is the first new drug solubilising agent in decades. Introduced in 2014 by chemist Matthias Barz from Leiden University, it offers a unique alternative to current options.

Bacteria carry countless hidden treasures in their DNA: fragments that could hold the key to new medicines. But how do you pick out the most promising ones from millions of options? ‘Look at the switches that turn genes on and off,’ says molecular biologist Gilles van Wezel.

For her bachelor’s thesis, Molecular Science and Technology student Madouc Bergers synthesized her own molecule that can inhibit the breakdown of sugars. Although most students do not even manage to make one building block, Madouc made three. Partly because of this, she has been nominated for the Science…